The study analyses 13C-ureagenesis in healthy subjects, UCD patients and carriers.
The population is the largest cohort to be studied to date.
The assay is a sensitive in-vivo tool to measure ureagenesis capacity.
It differentiates asymptomatic female carriers from symptomatic female OTCD patients.
It can contribute to the assessment of disease severity of neonatal OTCD patients.